The Pathway PV™ Atherectomy system is designed to treat the entire spectrum of disease found in the PAD patient. Our system has expandable, rotating scraping blades with aspiration for preemptive removal of both hard and soft plaque. The Pathway PV™ Atherectomy system provides simple set-up and easy operation to maximize effectiveness and minimize procedure time.
The Pathway PV™ Atherectomy System is not yet approved for sale and is subject to FDA 510(k) clearance.
Pathway Medical Technologies said Tuesday that it has raised $24.5 million in venture capital from existing investors — money geared to help the firm launch its first commercial product later this year.
The latest cash influx brings the total raised by the Kirkland-based medical-device maker to about $80 million, Chief Executive Tom Clement said. The company’s newly padded war chest should last it until revenue starts coming in from sales of its system for clearing out arterial plaque.
“We shouldn’t need another round of investment in the next year and a half, if that,” Clement said.
Pathway seeks to market a device to treat peripheral-arterial disease by sending a catheter with rotating blades up an artery to bore through accumulated fat and vacuum the debris away.
The device, under review by the U.S. Food and Drug Administration, is to be used in patients’ legs to improve circulation and prevent amputations. It could be an alternative to surgery and other methods, which include widening blood vessels and costly laser catheters that burn plaque away.
Pathway’s main rival is Fox Hollow, of Redwood City, Calif., which sells the SilverHawk, a catheter to remove plaque from peripheral arteries.